Navigation Links
Medarex Announces 2008 First Quarter Financial Results
Date:5/12/2008

PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter ended March 31, 2008.

Including a gain of $151.8 million, or $1.19 per share, from Medarex's sale of 2.5 million shares of Genmab A/S stock in February 2008, Medarex's net income for the quarter ended March 31, 2008, was $103.3 million, or $0.81 per share, as compared to a net income of $110.3 million, or $0.88 per share for the same period in 2007. In addition to the gain on the sale of Genmab A/S stock, Medarex's net income for the quarter ended March 31, 2008 included a loss of $2.9 million, or ($0.02) per share, representing Medarex's share of the 2008 net loss of Celldex Therapeutics, Inc. (a subsidiary of Medarex) prior to its merger with AVANT Immunotherapeutics, Inc., and a non-cash charge of $5.3 million, or ($0.04) per share, for stock-based compensation recorded in accordance with FAS 123(R). Excluding the impact of these items, Medarex's net loss on a non-GAAP basis for the first quarter of 2008 was $38.5 million, or ($0.30) per share.

Total revenues for the quarter ended March 31, 2008, were $12.0 million as compared to $11.5 million in 2007.

Research and development (R&D) expenses for the quarter ended March 31, 2008, increased by $2.3 million, from $47.0 million in 2007 to $49.3 million in 2008. General and administrative expenses increased by $1.1 million for the quarter ended March 31, 2008, from $11.3 million in 2007 to $12.4 million in 2008.

Medarex ended the first quarter of 2008 with approximately $464.5 million in cash, cash equivalents and marketable securities. In addition, the fair market value of Medarex's equity interest in Genmab was approximately $115.
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
2. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
3. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
6. Medarex to Present at the JPMorgan Small/Mid Cap Conference
7. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
8. Medifast Announces First Quarter 2008 Financial Results
9. Esperanza Announces Support of H.R. 1108, Encourages Congress to Pass FDA Regulation of Tobacco
10. Pregis Announces First Quarter 2008 Financial Results
11. Almost Family, Inc. Announces Exercise of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...team develops device giving patients freedom of mo...DAY, July 26 (HealthDay News) -- An automated arti...e day be to dialysis patients what the insulin pum...rable artificial kidney (AWAK) works better than c...current issue of Clinical and Experimental Nephro...
(Date:7/25/2008)...AKE SUCCESS, N.Y., July 25 /PRNewswire-USNewswire/...as Chief Quality Officer and Vice President,of Str...monwealth Fund, a,national foundation committed to...e directed the foundation,s Program on Health Care...p://www.newscom.com/cgi-bin/prnh/20080725/DC28791L...
(Date:7/25/2008)...red immune response after antiretroviral therapy m... July 25 (HealthDay News) -- A new study challenge...(HCV) impairs the immune system,s ability to resto...ly active antiretroviral therapy (HAART). , Fro...ers are also infected with HCV. Intravenous drug u...
(Date:7/25/2008)...he Authority offers patients consumers tips and en...ient safety, HARRISBURG, Pa., July 25 /PRNewswire...thority today supports "National Patient Safety Da...s and their families to,participate fully in their...thing they can about their surgery or illness., "...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3
...eloped a three-dimensional image of the AIDS virus...h aids in fusing// with human immune cells – An ex...agnosed. Findings from this AIDS research could ...ill thwart infection by targeting and crippling th...
... highly conducive for the cognitive development of...d//. Infact, even moderated alcohol intake during ... the unborn child. The study conducted by the Univ...ne and the University of Washington, has shown tha...
...the administration in WHO, to an agreement that wi...ent//. This is indeed a quantum leap in this field...ed. Moreover, it will also infuse renewed thrust i...h will in turn pave the way for novel methods to s...
...ing world statistics regarding the use of tobacco ...st one in five 13-15 year olds consume tobacco and...in the run up to the World Health Organization's W... years theme will revolve around the topic, ''toba...
Other Medicine News:Health News:Three-Dimensional Image Of AIDS Virus – BY FSU Researcher 2Health News:Three-Dimensional Image Of AIDS Virus – BY FSU Researcher 3
(Date:7/24/2008)...a Support Prognostic Value of Circulating Tumor Ce...ternational, prospective,clinical trial found the ...ng indicator of progression-free and overall survi...ccording to a report published in the July 1,issue... conducted in the US, the Netherlands, and the Uni...
(Date:7/24/2008)...HINGTON, July 24 /PRNewswire-USNewswire/ -- Headli...ot tell the whole story. The small scale,prelimin...e in Human,Reproduction, is based on recollected i...ning soyfoods. "This study is confounded by many,i...th a great deal of,caution," warned Dr. Tammy Hedl...
(Date:7/23/2008)...exavar is First Approved Systemic Therapy to Treat...., July 23 /-,Bayer HealthC... (Nasdaq:,ONXX) today announced that The New Engla...e 3 trial demonstrating that Nexavar(R) (sorafenib...31 percent in patients with,unresectable hepatocel...
(Date:7/23/2008)...S Study Finds Some Areas of the Body Have Greater ...Ill., July 23 /PRNewswire-USNewswire/ -- Fat remov...liposuction was found to be,an excellent source of...than other areas of the body, reports a Brazilian-... Surgery(R), the official medical journal of the,A...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Soyfoods Do Not Impact Sperm Count 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Nurses Doctors Patients to Protest Health Insurers at National Day of Action June 19th 21840 1Nurses Doctors Patients to Protest Health Insurers at National Day of Action June 19th 21840 2Alexion to Present at the William Blair 28th Annual Growth Stock Conference 5985 1How to Have Your Tomatoes and Eat Them Too 21838 1How to Have Your Tomatoes and Eat Them Too 21838 2How to Have Your Tomatoes and Eat Them Too 21838 3Emory study of syphilis bacteria yields valuable diagnostic tool 21836 1Emory study of syphilis bacteria yields valuable diagnostic tool 21836 2
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
The Wet-Field Coagulator provides precise episcleral, intrascleral, and intraocular hemostasis with reduced peripheral tissue trauma. Controlled Rf diathermy delivers targeted coagulation with the mo
Medicine Products: